



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1645
TECH CE
AUG 26 2003
RECEIVED

Applicant: Michael A. Apicella et al.

Title: VACCINE AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF NEISSERIAL INFECTIONS

Docket No.: 875.045US1

Serial No.: 10/066551

Filed: January 31, 2002

Due Date: N/A

Examiner: Padma Baskar

Group Art Unit: 1645

P#10

Commissioner for Patents
P.O.Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ An Supplemental Information Disclosure Statement (1 pg.), Form 1449 (1 pg.), and copies of 2 cited documents.
- ☒ A copy of the International Search Report mailed May 23, 2003 (10 pgs.).

If not provided for in a separate paper filed herewith, Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: Ann S. Viksnins
Atty: Ann S. Viksnins
Reg. No. 37,748

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450, on this 21st day of August, 2003.

LISA POSORSKE
Name

Lisa Posorske
Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
(GENERAL)

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)



S/N 10/066551

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael A. Apicella et al.

Examiner: Padma Baskar

Serial No.: 10/066551

Group Art Unit: 1645

Filed: January 31, 2002

Docket: 875.045US

Title: VACCINE AND COMPOSITIONS FOR THE PREVENTION AND
TREATMENT OF NEISSERIAL INFECTIONS

PATENT

AUG 28 2003

RECEIVED

TECHNICAL CENTER 1600/2500

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
P.O.Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97(c)(1) and 37 C.F.R. § 1.97(e)(1), Applicants state that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement. A copy of the International Search Report mailed May 23, 2003 is enclosed.

It is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

MICHAEL A. APICELLA ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6961

Date 20 August 2003

By Ann S. Viksnins
Ann S. Viksnins
Reg. No. 37,748

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, P.O.Box 1450, Alexandria, VA 22313-1450, on this 21st day of August, 2003

LISA POSORSKE
Name


Lisa Posorske
Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/066551
Filing Date	January 31, 2002
First Named Inventor	Apicella, Michael
Group Art Unit	1645
Examiner Name	Baskar, Padma

Sheet 1 of 1

Attorney Docket No: 875.045US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
--------------------	---------------------	------------------	---	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
--------------------	---------------------	------------------	---	-------	----------	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		EDWARDS, J. L., et al., "The Role of Complement Receptor 3 (CR3) in Neisseria Gonorrhoeae Infection of Human Cervical Epithelia", <u>Cellular Microbiology</u> , 3, (Sep. 2001), 611-622	
		FIJEN, C. A., et al., "The Role of Fc-gamma Receptor Polymorphisms and C3 in the Immune Defence Against Neisseria Meningitidis in Complement-Deficient Individuals", <u>Clinical and Experimental Immunology</u> , 120, (May 2000), 338-345	

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached